LEADING PATHOGENETIC FACTORS OF INTESTINAL SYNDROME FORMATION IN COVID-19
https://doi.org/10.34822/2304-9448-2021-4-74-79
Abstract
The study aims to review the scientific literature devoted to the analysis of leading pathogenetic factors of intestinal syndrome formation in novel coronavirus infection. Material and methods. The search of scientific literature was carried out in the following databases: Web of Science, Scopus, PubMed and RSCI using such keywords as coronavirus infection, intestinal syndrome. The search depth was 3 years. Results. As analysis of Russian and
foreign publications has shown, the pathogenesis of intestinal syndrome in COVID-19 is determined by the complex of such interconnected pathogenetic factors as cytokine storm, damage of microcirculatory bloodstream vessels with the development of microthrombosis, oxidative stress, hypoxia of mixed type, inflammation, and infectious intoxication.
About the Authors
V. T. Dolgikh
V. A. Negovsky Research Institute of General Reanimatology,
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow
Russian Federation
Russian Federation
Honored Science Worker of the Russian Federation, Doctor of Sciences (Medicine), Professor, Chief Researcher, Laboratory of Clinical Pathophysiology of Critical States
Е-mail: prof_dolgikh@mail.ru
T. I. Dolgikh
Penza Institute for Advanced Training of Doctors, Branch of the Russian Academy of Continuous Professional Education, Moscow
Russian Federation
Russian Federation
Doctor of Sciences (Medicine), Professor, Head, Department of Medical Microbiology and Laboratory Medicine
Е-mail: dolgih-ti@mail.ru
References
1. Шкурко Т. В., Веселов А. В., Князев О. В. и др. Особенности новой коронавирусной инфекции COVID-19 у пациентов с заболеваниями желудочно-кишечного тракта // Московская медицина. 2020. № 2 (36). С. 78–86.
2. South A. M., Diz D. I., Chappel M. C. COVID-19, ACE2 and the Cardiovascular Consequences // Am J Physiol Circ Physiol. 2020. Vol. 318, Is. 5. P. H1084–H1090. DOI 10.1152/ejoheart00217.2020.
3. Йокота Ш, Куройва Е., Нишиока К. Новая коронавирусная болезнь (COVID-19) и «цитокиновый шторм». Перспективы эффективного лечения с точки зрения патофизиологии воспалительного процесса // Инфекционные болезни: новости, мнение, обучение. 2020. № 9 (4). С. 13–25. DOI 10.33029/2305-3496-2020-9-4-13-25.
4. Xu Z., Shi L., Wang Y. et al. Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome // Lancet Respir Med. 2020. Vol. 8, Is. 4. P. 420–422. DOI 10.1016/S2213-2600(20)30076-X.
5. Mason R. J. Pathogenesis of COVID-19 From a Cell Biology Perspective // Eur Respir J. 2020. Vol. 55, Is. 4. P. 2000607. DOI 10.1183/13993003.00607-2020.
6. Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., Peng Z., Pan H. Clinical Features and Shortterm Outcomes of 221 Patients with COVID-19 in Wuhan, China // J Clin Virol. 2020. Vol. 127. P. 104364. DOI 10.1016/j.jcv.2020.104364.
7. Spiezia L., Boscolo A., Poletto F. et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure // Thromb Haemost. 2020. Vol. 120, Is. 6. P. 998–1000. DOI 10.1055/s-0040-1710018.
8. Merad M., Martin J. C. Pathological Inflammation in Patients with COVID-19: A Key Role for Monocytes and Macrophages // Nat Rev Immunol. 2020. Vol. 20, Is. 6. P. 355–362. DOI 10.1038/s41577-020-0331-4.
9. Varga Z., Flammer A. J., Steiger P. Endothelial Cell Infection and Endotheliitis in COVID-19 // Lancet. 2020. Vol. 395, Is. 10234. P. 1417–1418. DOI 10.1016/S0140-6736 (20)30937-5.
10. Цыган Н. В., Трашков А. П., Рябцев А. В. и др. Особенности симптоматики и патогенеза поражения центральной нервной системы при COVID-19 по данным клинических наблюдений: обзор // Общая реаниматология. 2021. № 17 (3). С. 65–77. DOI 10.15360/1813-9779-2021-3-65-77.
11. Vassiliou A. G., Kotanidou A., Dimopoulou I., Orfanos S. E. Endothelial Damage in Acute Respiratory Distress Syndrome // Int J Mol Sci. 2020. Vol. 21, Is. 22. P. 8793. DOI 10.3390/ijms21228793.
12. Yang D., Han Z., Oppenheim J. J. Alarmins and Immunity // Immunol Rev. 2017. Vol. 280, Is. 1. P. 41–56. DOI 10.1111/ imr.12577.
13. Zhang C., Wu Z., Li J.-W., Zhao H., Wang G.-Q. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality // J Antimicrob Agents. 2020. Vol. 55, Is. 5. P. 105954. DOI 10.1016/j.ijantimicag.2020.105954.
14. Fajgenbaum D. C., June C. H. Cytokine Storm // N Engl J Med. 2020. Vol. 383, Is. 23. P. 2255–2273. DOI 10.1056/ NEJMra2026131.
15. Pearce L., Davidson S. M., Yellon D. M. The Cytokine Storm of COVID-19: A Spotlight on Prevention and Protection // Expert Opin Ther Targets. 2020. Vol. 24, No. 8. P. 723–730. DOI 10.1080/25.14728222.2020.1783243.
16. Sisniega D. C., Reynolds A. S. Severe Neurologic omplications of SARS-CoV-2 // Curr Treat Options Neurol. 2021. Vol. 23, Is. 5. P. 14. DOI 10.1007/s11940-021-00669-1.
17. Li X., Xu S., Yu M. et al. Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan // J Allergy Clin Immunol. 2020. Vol. 146, Is. 1. P. 110–118. DOI 10.1016/j. jaci.2020.04.006.
18. Nardelli P., Landoni G. COVID-19-Related Thromboinflammatory Status: MicroCLOTS and Beyond // General Reanimatology. 2020. Vol. 16, No. 3. P. 14–15. DOI 10.15360/1813-9779-2020-3-0-2.
19. Kermali M., Khalsa R. K., Pillai K., Ismail Z., Harky A. The Role of Biomarkers in Diagnosis of COVID-19 – A Systematic Review // Life Sci. 2020. Vol. 254. P. 117788. DOI 10.1016/j.lfs.2020.117788.
20. Hirota K. Basic Biology of Hypoxic Responses Mediated by the Transcription Factor HIFs and Its Implication for Medicine // Biomedicines. 2020. Vol. 8, Is. 2. P. 32. DOI 10.3390/biomedicines8020032.
21. Bradshaw P. C., Seeds W. A., Miller A. C., Mahajan V. R., Curtis W. M. COVID-19: Proposing a Ketone-Based Metabolic Therapy as a Treatment to Blunt the Cytokine Storm // Oxid Med Cell Longev. 2020. Vol. 2020. P. 6401341. DOI 10.1155/2020/6401341.
22. Khomich O. A., Kochetkov S. N., Bartosch B., Ivanov A. V. Redox Biology of Respiratory Viral Infections // Viruses. 2018. Vol. 10, Is. 8. P. 392. DOI 10.3390/v10080392.
23. Badawy A. A.-B. Immunotherapy of COVID-19 withPoly (ADP-Ribose) Polymerase Inhibitors: Starting with Nicotinamide // Biosci Rep. 2020. Vol. 40, Is. 10. P. BSR20202856. DOI 10.1042/BSR20202856.
24. Cecchini R., Cecchini A. L. SARS-CoV-2 Infection Pathogenesis Is Related to Oxidative Stress as a Response to Aggression // Med Hypotheses. 2020. Vol. 143. P. 110102. DOI 10.1016/j.mehy.2020.110102.
25. Laforge M., Elbim C., Frère C. et al. Tissue Damage From Neutrophil Induced Oxidative Stress in COVID-19 // Nat Rev Immunol. 2020. Vol. 20, Is. 9. P. 515–516. DOI 10.1038/s41577-020-0407-1.
26. Teuwen L.-A., Geldhof V., Pasut A., Carmeliet P. COVID-19: The Vasculature Unleashed // Nat Rev Immunol. 2020. Vol. 20. P. 389–391. DOI 10.1038/s41577-020-0343-0.
27. Steven S., Frenis K., Oelze M. et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease // Oxid Med Cell Longev. 2019. Vol. 2019. P. 7092151. DOI 10.1155/2019/7092151.
28. Guan W.-J., Ni Z.-Y., Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China // N Engl J Med. 2020. Vol. 382, Is. 18. P. 1708–1720. DOI 10.1056/NEJMoa2002032.
29. Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, Is. 11. P. 1061–1069. DOI 10.1001/jama.2020.1585.
30. Lin L., Jiang X., Zhang Z. et al. Gastrointestinal Symptoms of 95 Cases with SARS-CoV-2 Infection // Gut. 2020. Vol. 69, Is. 6. P. 997–1001. DOI 10.11.36/gutjnl-2020-321013.
31. Song Y., Liu P., Shi X. L. et al. SARS-CoV-2 Induced Diarrhoea as Onset Symptom in Patient with COVID-19 // Gut. 2020. Vol. 69, Is. 6. P. 1143–1144. DOI 10.1136/gutjnl-2020-320891.
32. Gu J., Han B., Wang J. COVID-19 Gastrointestinal Manifestions and Potential Fecal-Oral Transmission // Gastroenterology. 2020. Vol. 158, Is. 6. P. 1831–1833. DOI 10.1053/j.gastro.2020.02.055.
33. Ивашкин В. Т., Шептулин А. А., Зольникова О. Ю. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2020. № 30 (3). С. 7–13. DOI 10/22416/1382-4376-2020-30-3-7.
Review
For citations:
Dolgikh V.T., Dolgikh T.I. LEADING PATHOGENETIC FACTORS OF INTESTINAL SYNDROME FORMATION IN COVID-19. Vestnik SurGU. Meditsina. 2021;(4 (50)):74-79. (In Russ.) https://doi.org/10.34822/2304-9448-2021-4-74-79
Views:
154
Email this article 
